首页> 外文OA文献 >Poor pricing progress: price disclosure isn’t the answer to high drug prices
【2h】

Poor pricing progress: price disclosure isn’t the answer to high drug prices

机译:定价进展不佳:价格披露不是高药价的答案

摘要

This report argues that Australia has a long way to go before consumers pay fair prices for pharmaceuticals.OverviewGrattan Institute’s March 2013 report, Australia’s bad drug deal, showed that Australians paid more than $1 billion a year too much for prescription drugs. The problem is how the government sets prices. Vested interests are involved in price negotiations, there is no cap on expenditure, and the price cuts when a drug goes off patent are far smaller than in many other countries.The problem hasn’t gone away. Current policies aren’t doing nearly enough to bring prices down. In December, the Commonwealth Government’s “price disclosure” policy led to price cuts for seven generic drugs. Price disclosure tracks discounts that manufacturers and wholesalers give to pharmacies. Then the government cuts prices to reflect what pharmacies actually pay.The price cuts in December averaged 34 per cent. In three cases the cuts were big enough to reduce out-of-pocket costs for patients. As a result patients without a concession now save around $5 for each box of pills.That sounds like a lot. But this report compares prices after these cuts with prices in the UK, New Zealand and the Canadian province of Ontario. On average, Australian prices remain almost 16 times higher than the best price in these three places. Our prices are more than 14 times higher than those in the UK.High prices are very costly for taxpayers and for consumers. Many Australians pay both through their taxes and then at the pharmacy.Once again, benchmarking against prices in other countries would get a much better deal. Of the seven drugs that had their prices reduced in December, patients would pay less for all of them, instead of just three. The out-of-pocket saving would also be much higher, averaging more than $21 per drug.The money we spend on high drug prices could be much better spent. But this isn’t just about saving money. Almost one in 10 Australians don’t take their prescribed medicine because of the cost. Better prices would help more people to buy the medicine they need.The Government should take three steps to cut the extremely high prices we pay for generic drugs. First, it should ask the Department of Health to release annual international comparisons of Australia’s drug prices. Everyone would then be able to see whether we are getting value for money.Second, when the current pricing agreement expires in July next year, there should be one-off benchmarking to get fair market prices. Finally, an independent drug pricing body should be established to make sure prices stay low in the future.
机译:这份报告认为,在消费者为药品支付公平价格之前,澳大利亚还有很长的路要走。概述格拉顿研究所(Grattan Institute)在2013年3月发布的澳大利亚不良药品交易报告显示,澳大利亚人每年为处方药支付的费用超过10亿澳元。问题在于政府如何定价。既得利益集团参与价格谈判,没有支出上限,而且药品获得专利权时的降价幅度远小于其他许多国家。问题没有解决。当前的政策还不足以降低价格。去年12月,英联邦政府的“价格公开”政策导致7种仿制药的降价。价格披露跟踪制造商和批发商给予药房的折扣。然后政府降低价格以反映药房实际支付的价格.12月的平均降价幅度为34%。在三种情况下,削减幅度足以减少患者的自付费用。结果,没有优惠的患者现在每盒药可以节省约5美元,这听起来很多。但本报告将降价后的价格与英国,新西兰和加拿大安大略省的价格进行了比较。平均而言,澳大利亚的价格仍比这三个地方的最高价格高出近16倍。我们的价格比英国高出14倍以上。高昂的价格对纳税人和消费者而言都是非常昂贵的。许多澳大利亚人既通过税收又通过药店支付,再一次以其他国家的价格为基准可以得到更好的交易。在12月份降价的7种药物中,患者将为所有这些药物支付的费用更低,而不仅仅是3种。自付费用的节省也将更高,平均每一种药物超过21美元,我们花在高药价上的钱可能会好得多。但这不只是为了省钱。由于费用高昂,几乎十分之一的澳大利亚人不服用处方药。较高的价格将帮助更多的人购买所需的药品。政府应采取三步措施,降低我们为仿制药支付的极高价格。首先,它应该要求卫生部发布澳大利亚药品价格的年度国际比较数据。然后,每个人都可以看到我们是否在物有所值。其次,当当前的定价协议于明年7月到期时,应该有一个一次性基准以获取公平的市场价格。最后,应该建立一个独立的药品定价机构,以确保未来价格保持较低水平。

著录项

  • 作者

    Stephen Duckett; Peter Breadon;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号